Zymeworks (NYSE: ZYME)
Zymeworks Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Zymeworks Company Info
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab’s unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
News & Analysis
Why Shares of Zymeworks Rose 12.18% on Monday
The biotech stock's shares may have been pushed by a short squeeze.
Why Zymeworks Stock Is Soaring Today
Investors applauded a major licensing deal with Jazz Pharmaceuticals.
Why Zymeworks Stock Is Rocketing Higher on Friday
New cancer trial results from the clinical-stage biopharmaceutical company inspired a juicy buyout offer.
Is It Too Late to Buy Zymeworks Stock?
The clinical-stage antibody treatment developer has a fair way to go before it gets a product to market -- but it's not going it alone.
Why Zymeworks Stock Is Crashing Today
The company announced early data for an experimental cancer drug that disappointed investors.
3 Top Biotech Picks for 2025
The opportunity is vast for Ontrak, Nano-X Imaging, and Zymeworks.
Billionaires Are Gobbling Up These 3 Healthcare Stocks
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
3 Canadian Biotechs to Consider Buying Today
These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.